Lyell Immunopharma, Inc. LYEL
Set alert
10.88 USD 0.00 0.00%
At close · Nov 2
10.88 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
Day range unavailable
7.20 52-week range 45.00
- YTD
- -64.65%
- 1 year
- -34.69%
- Open
- —
- Prev close
- 10.88
- Mkt cap
- 266.62M
- Vol
- 0
- Avg vol
- 151.38K
- EPS
- -12.86
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -0.73
- Beta
- -0.48
- Short ratio
- 6.15
- Inst. own
- 58.79%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.01
- 200-d avg
- 1.68
- 1y target
- 1.00
Analyst view
Consensus: hold
Hold
Price target (mean) 1.00
Ratings (0m) 4 0 buy · 3 hold · 1 sell
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell1
Recommendation trend
- This month 4
- 1 month ago 4
- 2 months ago 4
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.13 | -0.13 – -0.13 | -0.1737 | +25.2% | 0 | -100.0% | 1 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Current year | -0.58 | -0.58 – -0.58 | -0.707 | +18.0% | 27.33K | -79.0% | 1 |
| Next year | -0.45 | -0.45 – -0.45 | -0.58 | +22.4% | 0 | -100.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 12, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Oct 30, 2024 | B of A Securities | Downgrade | Buy | Underperform |
| Oct 28, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Aug 19, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Jun 27, 2024 | B of A Securities | Maintained | Buy | Buy |
| Jun 27, 2024 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| May 7, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 29, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 9, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 28, 2023 | JP Morgan | Downgrade | Overweight | Neutral |
| May 5, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 2, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Jan 24, 2023 | Morgan Stanley | Maintained | — | Equal-Weight |
| Nov 14, 2022 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Nov 11, 2022 | Goldman Sachs | Downgrade | Buy | Neutral |
| Oct 17, 2022 | HC Wainwright & Co. | Initiated | — | Buy |
| May 24, 2022 | Goldman Sachs | Maintained | — | Buy |
| Mar 31, 2022 | Goldman Sachs | Maintained | — | Buy |
| Jan 6, 2022 | Morgan Stanley | Maintained | — | Overweight |
| Jul 12, 2021 | Morgan Stanley | Initiated | — | Overweight |
| Jul 12, 2021 | B of A Securities | Initiated | — | Buy |
| Jul 12, 2021 | JP Morgan | Initiated | — | Overweight |
| Jul 12, 2021 | Goldman Sachs | Initiated | — | Buy |